London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

A good cosmetic solution for recurrent pterigium: autologous limbal-conjuctival autografting

Poster Details

First Author: M.Gil Martinez SPAIN

Co Author(s):    R. Touriã‘O-Peralba   L. Martinez-Perez   M. Treus-Suarez   M. Santos-Ramos   M. Rodriguez-Ares  

Abstract Details

Purpose:

To evaluate cosmetic results of autologous limbal conjuctival autografting using fibrin glue adhesive in recurrent pterygium.

Setting:

Complejo Hospitalario Universitario Santiago de Compostela

Methods:

Retrospective case series study of 20 patients who underwent limbal-conjuctival autografting using fibrin tissue glue in recurrent pterygium. We analysed cosmetic result, inflammation prior surgery, number of recurrences previous surgery, follow-up period, use of immunosuppression and complications after surgery.

Results:

We analysed 20 patients (10 males and 10 females) diagnosed of recurrent pterygium. The mean age was 58,36± 12,87.All patients present mean of 2 recurrences prior surgery. All patient underwent limbal-conjunctival autografting using local immunosuppression, we pre-treated them prior the surgery, in 20% of patient we used 0.02 % Mitomicin C. The mean follow up period was 44 ± 27,79 months and during this period the recurrence rate was 10%.Only one patient present a conjunctival cyst after surgery which was successfully removed in a second surgery. Only one patient present dehiscence related with the use of fibrin tissue glue.

Conclusions:

Limbal conjuctival autografting is a good cosmetic solution in patients with recurrent pterygium appears to be safe and effective method to reduce recurrence rate.

Financial Disclosure:

NONE

Back to Poster listing